Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application
Clinical and Translational Medicine · 2024-11 · 14 (11)
DOI: 10.1002/ctm2.70066 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 27.10.2024. Verfasst von Lin Su und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: DNA Methylation, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 346 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a primary malignant tumour, ranking second in global mortality rates and posing significant health threats. Epigenetic alterations, particularly DNA methylation, have emerged as pivotal factors associated with HCC diagnosis, therapy, prognosis and malignant progression. However, a comprehensive analysis of the DNA methylation mechanism driving HCC progression and its potential as a therapeutic biomarker remains lacking. This review attempts to comprehensively summarise various aspects of DNA methylation, such as its mechanism, detection methods and biomarkers aiding in HCC diagnosis, treatment and prognostic assessment of HCC. It also explores the role of DNA methylation in regulating HCC's malignant progression and sorafenib resistance, alongside elaborating the therapeutic effects of DNA methyltransferase inhibitors on HCC. A detailed examination of these aspects underscores the significant research on DNA methylation in tumour cells to elucidate malignant progression mechanisms, identify diagnostic markers and develop new tumour‐specific inhibitors for HCC. Key points A comprehensive summary of various aspects of DNA methylation, such as its mechanism, detection methods and biomarkers aiding in diagnosis and treatment. The role of DNA methylation in regulating hepatocellular carcinoma's (HCC) malignant progression and sorafenib resistance, alongside elaborating therapeutic effects of DNA methyltransferase inhibitors. Deep research on DNA methylation is critical for discovering novel tumour‐specific inhibitors for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Colorectal Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Operation Room, The First Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
ORCID-Profile: Xudong Zhu
Zitieren
APA
Su, L., Bu, J., Yu, J., Jin, M., Meng, G., & Zhu, X. (2024). Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application. Clinical and Translational Medicine, 14(11). https://doi.org/10.1002/ctm2.70066
Vancouver
Su L, Bu J, Yu J, Jin M, Meng G, Zhu X. Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application. Clinical and Translational Medicine. 2024;14(11). doi:10.1002/ctm2.70066
BibTeX
@article{Su2024,
author = {Su, Lin and Bu, Jiawen and Yu, Jiahui and Jin, Mila and Meng, Guanliang and Zhu, Xudong},
title = {Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application},
journal = {Clinical and Translational Medicine},
year = {2024},
volume = {14},
number = {11},
doi = {10.1002/ctm2.70066}
}
EUVIMED